MINNEAPOLIS--(BUSINESS WIRE)--Signaling a new frontier in the use of transcatheter valve technology, Medtronic, Inc. (NYSE:MDT) announced today that it has received CE Mark approval for its Melody™ Transcatheter Pulmonary Valve and Ensemble™ Transcatheter Delivery System. The system is the first of its kind worldwide to treat congenital patients with structural heart disease requiring pulmonary heart valve replacement.
